World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
28219
World Ranking
13632
National Ranking
433

Norbert Vey publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Norbert Vey sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 856 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Norbert Vey D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Norbert Vey sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Norbert Vey is affiliated with Aix-Marseille University in France and has a substantial research record primarily focused on hematology and related medical fields. Their work is positioned at the intersection of medicine, hematology, immunology, molecular biology, oncology, and genetics.

The scientist's research topics prominently include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Immune Cell Function and Interaction
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Norbert Vey has contributed extensively to the literature on acute myeloid leukemia (AML) and related disorders. Some notable publications include:

  • "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia", Blood, 2020
  • "Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation", Haematologica, 2020
  • "Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia", The Journal of Experimental Medicine, 2021
  • "Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort", Blood Advances, 2021
  • "Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study", Blood, 2021

The scientist frequently publishes in high-impact and specialized journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, Leukemia, Blood Advances, and European Journal Of Haematology. Their publication volume is highest in Blood, accounting for 49 publications.

Collaborative work characterizes Norbert Vey's research approach, with frequent co-authors including:

  • Christian Récher (44 joint publications)
  • Sylvain Garciaz (42 joint publications)
  • Yosr Hicheri (29 joint publications)
  • Arnaud Pigneux (28 joint publications)
  • Pierre Péterlin (24 joint publications)

Their contributions advance understanding and treatment approaches in hematopoietic stem cell transplantation and immune cell function among other areas. Norbert Vey's research activities align closely with clinical applications and experimental medicine related to leukemia and myelodysplastic syndromes. The breadth of their work covers molecular and clinical aspects spanning immunology, genetics, and oncology.

Best Publications

  • Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

    Véronique Gelsi-Boyer;Virginie Trouplin;José Adélaïde;Julien Bonansea

  • OUTCOME OF TREATMENT IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: ANALYSIS OF THE LALA-94 TRIAL

    Xavier Thomas;Jean Michel Boiron;Françoise Huguet;Hervé Dombret

  • Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

    R Itzykson;O Kosmider;T Cluzeau;V Mansat-De Mas

  • Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

    Raphaël Itzykson;Olivier Kosmider;Aline Renneville;Véronique Gelsi-Boyer

  • Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

    Thomas Prébet;Steven D. Gore;Benjamin Esterni;Claude Gardin

  • Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

    Raphael Itzykson;Sylvain Thépot;Bruno Quesnel;Francois Dreyfus

  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

    Céline Berthon;Emmanuel Raffoux;Xavier Thomas;Norbert Vey

  • Mutations of ASXL1 gene in myeloproliferative neoplasms

    N Carbuccia;A Murati;V Trouplin;M Brecqueville

  • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

    Eric Jourdan;Nicolas Boissel;Sylvie Chevret;Eric Delabesse

  • Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

    Ruxanda Moschoi;Ruxanda Moschoi;Véronique Imbert;Véronique Imbert;Marielle Nebout;Marielle Nebout;Johanna Chiche;Johanna Chiche

  • Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

    Sophie Park;Sophie Grabar;Charikleia Kelaidi;Odile Beyne-Rauzy

  • Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

    Sébastien Maury;Sylvie Chevret;Xavier Thomas;Dominik Heim

  • TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

    Olivier Kosmider;Véronique Gelsi-Boyer;Meyling Cheok;Sophie Grabar

  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

    Lionel Adès;Lionel Adès;Agnes Guerci;Emmanuel Raffoux;Miguel Sanz

  • Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

    Marie Balsat;Aline Renneville;Xavier Thomas;Stéphane de Botton

  • Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

    Frederik Damm;Olivier Kosmider;Véronique Gelsi-Boyer;Véronique Gelsi-Boyer;Aline Renneville

  • A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

    Norbert Vey;Jean-Henri Bourhis;Nicolas Boissel;Dominique Bordessoule

  • Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

    O Kosmider;V Gelsi-Boyer;L Slama;F Dreyfus

  • TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

    Olivier Kosmider;Véronique Gelsi-Boyer;Marion Ciudad;Cindy Racoeur

  • Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

    E. Tavernier;J. M. Boiron;F. Huguet;K. Bradstock

Frequent Co-Authors

Christian Recher
Christian Recher Federal University of Toulouse Midi-Pyrénées
Daniel Olive
Daniel Olive Aix-Marseille University
Patrice Viens
Patrice Viens Aix-Marseille University
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Hervé Dombret
Hervé Dombret Université Paris Cité
Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Eric Delabesse
Eric Delabesse Cancer Research Center of Toulouse

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the traditional path to becoming a doctor. Today, there are a variety of medical billing and coding online programs that offer flexible entry points into healthcare administration. These courses are an excellent introduction for those interested in the crucial behind-the-scenes elements of medical practice.

Nursing remains one of the most in-demand healthcare careers. If you’re looking to minimize tuition costs, consider one of the cheapest online BSN programs to kickstart your nursing journey. Registered nurses seeking advancement may find value in researching the cheapest NP school options for nurse practitioner credentials.

For experienced nurses aiming for leadership, teaching, or research roles, affordable doctoral programs are available. Aspiring nurse leaders can explore the cheapest DNP programs online to maximize career growth while managing costs.

With a range of budget-friendly online healthcare degrees, students can find academic pathways that match both their aspirations and financial situations.

Best Scientists Citing Norbert Vey

Trending Scientists

Recently Published Articles